期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奥沙利铂与培美曲塞在中晚期肺癌化疗中的成本效果分析 被引量：1

暂未订购
导出
摘要 目的:探讨奥沙利铂与培美曲塞在中晚期肺癌化疗中的成本效果。方法:将中晚期肺癌患者60例根据治疗方法的不同分为治疗组与对照组,每组30例,在常规治疗基础上,治疗组采用培美曲塞二钠化疗,对照组采用奥沙利铂治疗。结果:治疗组的总有效率为93.3%,而对照组为66.7%,治疗组疗效明显好于对照组(P<0.05)。治疗组的C/E值明显高于对照组,差异有统计学意义(P<0.05)。结论:培美曲塞在中晚期肺癌治疗中的疗效好于奥沙利铂,但是临床成本高于奥沙利铂,临床上要根据实际情况合理选择药物。
作者 卢欣
机构地区 广西河池市中医医院药剂科
出处 《吉林医学》 CAS 2014年第6期1203-1203,共1页 Jilin Medical Journal
关键词 奥沙利铂 培美曲塞 中晚期肺癌
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献30

  • 1[1]Central European Cooperative Oncology Group (CECOG); Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncology (ESO); Vienna Medical Association, Consensus on medical treatment of non-small cell lung cancer. Lung Cancer,2002,38(Suppl 3)∶S3-S7.
  • 2[3]Abeloff MD, Armitage JO, Lichter AS, et al eds. Clinical Oncology 2 ed. Singapore: HARCOURT ASIA,1999.1423-1426.
  • 3[4]Hansen HH eds. Textbook of lung cancer. 1ed. London: Martin Dunitz,2000.230-233.
  • 4[5]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol,2000,18(12)∶2354-2362.
  • 5[8]Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer,1998,20(2)∶85-91.
  • 6[9]Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol,2002,21∶298a.
  • 7[10]Kris RB, Natale RS, Herbst TJ, et al. A phase Ⅱ trial of ZD1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol,2002,21∶292a.
  • 8[11]Giaccone G, Johnson DH, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-native patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol,2002,13(Suppl 5)∶2-3.
  • 9[12]Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-native patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase Ⅲ clinical trial (INTACT 2). Ann Oncol,2002,13(Suppl 5)∶127-128.
  • 10[13]Fujiwara K, Kiura K, Ueoka H, et al. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small cell lung cancer and poor performance status. Lung Cancer,2003,40(1)∶73-76.

共引文献101

同被引文献4

引证文献1

吉林医学
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部